We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
51
Supernus Pharmaceuticals
SUPN
$2.78B
$3.34M 0.63%
164,000
-277,000
-63% -$4.91M
ACHN
52
DELISTED
Achillion Pharmaceuticals
ACHN
$3.28M 0.62%
420,000
– –
AET
53
DELISTED
Aetna Inc
AET
$3.16M 0.6%
25,900
-19,100
-42% -$2.19M
TMO icon
54
Thermo Fisher Scientific
TMO
$197B
$2.96M 0.56%
20,000
– –
MNK
55
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$2.86M 0.54%
47,000
-41,000
-47% -$2.51M
ALKS icon
56
Alkermes
ALKS
$8.68B
$2.83M 0.53%
65,500
– –
LLY icon
57
Eli Lilly
LLY
$1.03T
$2.76M 0.52%
35,000
– –
SGEN
58
DELISTED
Seagen Inc. Common Stock
SGEN
$2.75M 0.52%
68,000
– –
HALO icon
59
Halozyme
HALO
$9.19B
$2.74M 0.52%
318,000
– –
IPXL
60
DELISTED
Impax Laboratories, Inc.
IPXL
$2.74M 0.52%
95,000
-13,000
-12% -$424K
MRK icon
61
Merck
MRK
$309B
$2.71M 0.51%
49,256
-13,624
-22% -$725K
NVDQ
62
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.66M 0.5%
270,000
– –
XENT
63
DELISTED
Intersect ENT, Inc
XENT
$2.65M 0.5%
205,325
-3,921
-2% -$61.4K
NKTR icon
64
Nektar Therapeutics
NKTR
$2.22B
$2.65M 0.5%
12,400
-2,000
-14% -$447K
NBIX icon
65
Neurocrine Biosciences
NBIX
$17.5B
$2.64M 0.5%
58,000
-7,000
-11% -$322K
IONS icon
66
Ionis Pharmaceuticals
IONS
$8.86B
$2.52M 0.47%
108,000
-30,000
-22% -$968K
NVAX icon
67
Novavax
NVAX
$1.31B
$2.36M 0.44%
16,250
– –
MGNX icon
68
MacroGenics
MGNX
$278M
$2.24M 0.42%
83,000
– –
IBB icon
69
iShares Biotechnology ETF
IBB
$9.32B
$2.19M 0.41%
25,500
+18,000
+240% +$1.62M
ANGO icon
70
AngioDynamics
ANGO
$566M
$2.18M 0.41%
151,400
– –
GMED icon
71
Globus Medical
GMED
$10.4B
$2.09M 0.39%
87,700
– –
QGENF
72
DELISTED
QIAGEN NV
QGENF
$2M 0.38%
91,500
– –
HZNP
73
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.93M 0.36%
117,000
-193,000
-62% -$3.12M
ICPT
74
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.93M 0.36%
13,500
– –
ELV icon
75
Elevance Health
ELV
$83.4B
$1.84M 0.35%
14,000
-16,000
-53% -$2.19M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.